GLP-1 Medications and Testosterone: What the Research Shows

*Compounded semaglutide and compounded tirzepatide are not FDA-approved. This article is for educational and informational purposes only and does not constitute medical advice. Clinical data referenced here reflects studies of FDA-approved pharmaceutical compounds unless otherwise noted. Individual results vary. Consult your licensed healthcare provider before starting, stopping, or adjusting any medication. Care at Prescriva is delivered by independently licensed providers, not by Blue Oak Services LLC dba Prescriva, which is a management services organization.*

---

There is a conversation happening in men's health clinics that often surprises the men sitting in the exam chair.

They came in because they had gained weight. They leave with a question about their testosterone.

The two are connected in ways that most people do not fully understand. And over the last several years, a growing body of research has begun to clarify exactly how GLP-1 medications fit into this picture. Not as a testosterone therapy, which they are not. But as a weight-loss intervention that may address one of the most common, and commonly missed, causes of low testosterone in men.

---

Why Obesity and Low Testosterone Are Linked

Testosterone does not exist in isolation. Its production is regulated by a feedback loop involving the hypothalamus, the pituitary gland, and the testes. This is called the hypothalamic-pituitary-gonadal (HPG) axis. When excess body fat accumulates, particularly in the abdomen, that axis can be disrupted in several ways.

The most direct mechanism involves an enzyme called aromatase. Fat tissue, especially visceral fat, contains high concentrations of aromatase. This enzyme converts testosterone into estradiol, a form of estrogen. As fat mass increases, so does aromatase activity, and circulating testosterone can drop as a result.

At the same time, obesity raises insulin resistance and lowers sex hormone-binding globulin (SHBG), the protein that carries testosterone through the bloodstream. Lower SHBG can affect how much testosterone is biologically available to tissues. And elevated leptin levels, which are common in obesity, may directly suppress testicular testosterone production.

The result of this cascade is what researchers call obesity-related, or functional, hypogonadism. Unlike primary hypogonadism caused by testicular damage, or secondary hypogonadism caused by a pituitary disorder, functional hypogonadism is tied to metabolic state. That distinction matters because it means the condition may be reversible if the underlying metabolic driver, excess body fat, is addressed.

---

What the Research Shows About GLP-1 Medications and Testosterone

A 2025 systematic review and meta-analysis published in *BMC Urology* analyzed the available evidence on GLP-1 receptor agonists and testosterone levels in men. The review, conducted by Orra and colleagues, found that treatment with GLP-1 medications was associated with statistically significant increases in total testosterone across the studies examined (PMID 41291666).

The effect was not uniform. Men who lost more weight tended to see larger improvements in testosterone. This is consistent with what we know about functional hypogonadism: when the metabolic driver is reduced, the HPG axis can begin to recover.

A 2026 systematic review and meta-analysis published in *Andrology* went further. Corona and colleagues examined both GLP-1 receptor agonists and SGLT2 inhibitors, comparing their effects on male sexual hormones and behaviors. The analysis found that GLP-1 agonists were associated with improvements in total testosterone, with effects that became more pronounced as body weight decreased (PMID 42011503). The researchers also noted favorable trends in luteinizing hormone (LH), a pituitary signal that drives testosterone production, suggesting the HPG axis was responding, not just peripheral testosterone clearance.

A separate 2026 systematic review focusing specifically on reproductive outcomes added another layer. Published in the *Journal of Sexual Medicine*, it examined GLP-1 receptor agonists across male reproductive endpoints including testosterone, semen parameters, and metabolic markers. The review concluded that weight loss achieved through GLP-1 therapy was consistently associated with improvements in gonadal function, and that this appeared to be mediated primarily through the reduction in adipose tissue and its downstream effects on aromatase activity and the HPG axis (PMID 41498523).

Perhaps the most specific clinical evidence comes from a 2025 study published in *Diabetes, Obesity and Metabolism*. Gregorič and colleagues studied obese men with type 2 diabetes and functional hypogonadism who were treated with semaglutide. After treatment, the researchers observed improvements not only in testosterone levels but in sperm morphology as well. The improvements correlated with reductions in body weight and waist circumference, lending further support to the fat-driven aromatase mechanism (PMID 39511836).

---

What This Means in Practice

These findings point toward a clinically meaningful insight. For a subset of men with obesity, low testosterone may not require testosterone replacement therapy. It may require treating the obesity that caused the hormonal disruption in the first place.

This does not mean GLP-1 medications are a testosterone treatment. They are not. The studies reviewed above looked at men undergoing GLP-1 therapy for weight management and metabolic health, and testosterone improvement was a secondary finding. No GLP-1 medication is approved, compounded or branded, for the purpose of raising testosterone.

What the research does suggest is that for men with obesity-related functional hypogonadism, the path to hormonal normalization may run through weight loss. GLP-1 medications, when prescribed by a licensed provider after a thorough medical evaluation, are among the more effective tools available for achieving meaningful, sustained weight loss.

A 2026 review of male hypogonadism published in *JAMA* by Anawalt and colleagues reinforced this clinical framing: obesity-related functional hypogonadism is a recognized condition, distinct from primary or secondary hypogonadism, and weight loss is considered a primary management strategy before testosterone replacement is initiated in appropriate candidates (PMID 42207626).

---

Who May See Hormonal Benefits From GLP-1 Therapy

Not every man on a GLP-1 program will experience a meaningful testosterone increase. A few factors appear to predict who responds most strongly:

Higher starting BMI. The obesity-aromatase mechanism is most pronounced in men with significant visceral adiposity. Men who lose more weight tend to see greater hormonal improvements.

Functional rather than primary hypogonadism. If low testosterone is caused by testicular damage, a genetic condition, or a structural pituitary issue, weight loss alone is unlikely to restore normal levels. A thorough hormonal workup by a licensed provider can help clarify which type of hypogonadism is present.

No prior testosterone replacement therapy. Exogenous testosterone suppresses natural production through the HPG axis. Men who have been on testosterone replacement for extended periods may have a more complex recovery trajectory.

Degree of weight loss achieved. The evidence is consistent that testosterone improvements scale with weight loss. Modest weight reduction may yield modest hormonal changes; more significant weight loss tends to produce more meaningful shifts.

---

What About Tirzepatide?

Most of the direct evidence on GLP-1 medications and testosterone has been generated using semaglutide, which has a longer evidence record. Tirzepatide, which targets both GLP-1 and GIP receptors, is a newer agent with a less developed literature in this area.

However, the mechanistic case is straightforward. If the testosterone benefit from GLP-1 therapy is primarily weight-loss driven, and tirzepatide produces substantial weight loss, the downstream hormonal effects should follow a similar pattern. A 2026 pilot study published in *Minerva Endocrinologica* examined tirzepatide in obese hypogonadal men and explored the role of add-on testosterone therapy in men who did not fully respond to tirzepatide alone. The study found that tirzepatide did produce improvements in testosterone in most participants, with a subset requiring adjunctive therapy (PMID 41801155). This suggests the hormonal response to tirzepatide follows a similar trajectory to semaglutide, with individual variability.

Dedicated studies examining tirzepatide's effects on male hormones are ongoing. The broader GLP-1 mechanism makes it biologically plausible that tirzepatide will demonstrate comparable hormonal benefits as the evidence matures.

---

The Conversation to Have With Your Provider

If you are a man with obesity and you have noticed symptoms associated with low testosterone, including low energy, reduced libido, mood changes, or difficulty with physical performance, it is worth raising this with your healthcare provider before assuming you need testosterone replacement.

Testosterone levels should be tested in the morning when they are highest, and at least twice before a diagnosis of hypogonadism is made. Your provider will also want to rule out other causes of low testosterone before attributing it to obesity.

If functional hypogonadism is confirmed, weight loss is typically the first clinical recommendation. For men who have struggled with weight loss through lifestyle changes alone, a medically supervised GLP-1 program may be worth discussing with a licensed provider. GLP-1 medications are most effective when combined with diet and exercise, and they carry side effects. The most common include nausea, vomiting, diarrhea, and constipation, and more serious risks are possible. GLP-1 medications are not appropriate for everyone, and the decision to prescribe them requires a full clinical evaluation.

The goal is not to replace one treatment with another. It is to understand what is driving the hormone disruption and address that root cause, with the support of providers who can monitor your progress, adjust your plan, and help you make decisions that are right for your specific health situation.

---

*This article discusses research findings related to GLP-1 medications and testosterone in the context of obesity. It does not constitute medical advice, a diagnosis, or a treatment recommendation.*

*Compounding disclaimer: Compounded semaglutide and compounded tirzepatide are not FDA-approved medications. They are not reviewed by the FDA for safety, efficacy, or quality. Compounded semaglutide is not the same as, equivalent to, or interchangeable with FDA-approved semaglutide products (Ozempic, Wegovy, or Rybelsus). Compounded tirzepatide is not the same as Mounjaro or Zepbound.*

*Results disclaimer: Individual results vary. Weight management outcomes depend on adherence to your prescribed treatment plan, diet, exercise, starting weight, and other individual health factors. Results are not guaranteed.*

*Provider disclaimer: All medical services, including prescribing, are provided by independently licensed healthcare providers. Blue Oak Services LLC dba Prescriva is a management services organization and does not practice medicine or make clinical decisions.*

*Brand disclaimer: Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Prescriva is not affiliated with, endorsed by, or sponsored by these companies.*